RCAP
MLTX icon

Resolute Capital Asset Partners’s MoonLake Immunotherapeutics MLTX Stock Holding History

Resolute Capital Asset Partners’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-24,541
Closed -$1.23M – 55
2024
Q1 		$1.23M Buy
+24,541
New +$1.33M 0.64% 36

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Resolute Capital Asset Partners's MLTX Position: Q2 2024 in Review

Resolute Capital Asset Partners sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2024, closing a stake of 24,541 shares — an estimated $1.23M sold.

Resolute Capital Asset Partners first reported a position in MLTX in Q1 2024 and held it in 1 quarter. The position peaked at $1.23M in Q1 2024. 111 funds tracked by Wall St. Rank hold MLTX as of Q2 2024.

  • Resolute Capital Asset Partners reported no remaining MoonLake Immunotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Resolute Capital Asset Partners sold 24,541 MoonLake Immunotherapeutics shares in Q2 2024, an estimated $1.23M.
  • Resolute Capital Asset Partners first reported a position in MoonLake Immunotherapeutics in Q1 2024 and held it in 1 quarter.
  • Resolute Capital Asset Partners's MoonLake Immunotherapeutics position peaked at $1.23M in Q1 2024.
  • 111 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2024.

Based on Resolute Capital Asset Partners's 13F filing for Q2 2024, filed 12 Aug 2024.